Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published December 21, 2018 | Accepted Version + Supplemental Material
Journal Article Open

Functional TCR T cell screening using single-cell droplet microfluidics

Abstract

Adoptive T cell transfer, in particular TCR T cell therapy, holds great promise for cancer immunotherapy with encouraging clinical results. However, finding the right TCR T cell clone is a tedious, time-consuming, and costly process. Thus, there is a critical need for single cell technologies to conduct fast and multiplexed functional analyses followed by recovery of the clone of interest. Here, we use droplet microfluidics for functional screening and real-time monitoring of single TCR T cell activation upon recognition of target tumor cells. Notably, our platform includes a tracking system for each clone as well as a sorting procedure with 100% specificity validated by downstream single cell reverse-transcription PCR and sequencing of TCR chains. Our TCR screening prototype will facilitate immunotherapeutic screening and development of T cell therapies.

Additional Information

© 2018 The Royal Society of Chemistry. The article was received on 07 Aug 2018, accepted on 26 Oct 2018 and first published on 06 Nov 2018. This article is part of the themed collections: Lab on a Chip Emerging Investigators and Droplet-based single-cell sequencing. The authors would like to thank Chih Chun Yu for his help in finishing the TCR T cell activation experiments in droplets and assistance in droplet sorting, and Stephanie Wong for her help in single cell PCR work. The authors are also grateful to Cassandra Kiyomi Davis for her support in culturing the cells and performing cell viability test from droplets. This work is supported by the NIH (1DP2CA195763 and R21CA219225), and Amberstone Biosciences LLC: No. AB-208317. Author contributions: Conceptualization, A. I. S., G. L., G. W. and W. Z.; methodology, A. I. S., G. L., L. K., C. R., X. C. and G. W.; investigation, A. I. S, G. L., L. K., C. R., and J. K. W.; analysis, A. I. S.; writing: original draft, A. I. S. and W. Z.; editing, A. I. S., G. L., L. K., X. C., J. K. W., D. B., G. W. and W. Z.; supervision, A. I. S., D. B., G. W. and W. Z. Conflicts of interest: Weian Zhao is a co-founder of Amberstone Biosciences LLC that develops immunotherapeutics.

Attached Files

Accepted Version - nihms-996455.pdf

Supplemental Material - c8lc00818c1.pdf

Supplemental Material - c8lc00818c2.pdf

Supplemental Material - c8lc00818c3.avi

Supplemental Material - c8lc00818c4.avi

Supplemental Material - c8lc00818c5.avi

Supplemental Material - c8lc00818c6.avi

Files

c8lc00818c2.pdf
Files (27.4 MB)
Name Size Download all
md5:f33e8cbec84c639ecfe54cf198d3ea2a
114.8 kB Preview Download
md5:49c4a60db41504eba947994039af08c4
7.2 MB Download
md5:03d957398080b6ad9b9bab31a24a458f
5.3 MB Download
md5:7527b0128ab38b7d3dfa16b3b6055d58
1.5 MB Download
md5:cc7fed594efd38198fb2be5554835237
2.7 MB Preview Download
md5:0eb6bedb799454dd61ea27fd0d4b6dbe
296.4 kB Preview Download
md5:e2bd73667be04cfb08329ac41b569a62
10.3 MB Download

Additional details

Created:
August 19, 2023
Modified:
October 19, 2023